News

Patients with PBC may suffer a greater risk of developing osteoporosis, but researchers have not yet identified a definitive relationship between the two.

A recent study shows a high neutrophil-to-lymphocyte ratio may predict poor response to ursodeoxycholic acid in primary biliary cholangitis (PBC).

The FDA has accepted a New Drug Application (NDA) for elafibranor, an investigational therapeutic for the treatment of primary biliary cholangitis (PBC).

Treatment with elafibranor may improve bile flow in patients with primary biliary cholangitis (PBC), according to results of a phase 3 trial.

A study shows deep learning can be used to guide treatment, predict ALBI scores, dose UDCA and prevent use of multiple drugs in elderly adults with PBC.

Treatment of primary biliary cholangitis (PBC) with obeticholic acid may reduce negative outcomes in the disease, according to a study.

Seeking a Priority Review designation, CymaBay anticipates that the FDA will conclude its evaluation of the PBC treatment within six months.

The prevalence of primary biliary cholangitis (PBC) in the U.S. may be high and variable between regions, according to a recent study.

High blood levels of fats such as triglycerides and cholesterol in patients with PBC may not increase their risk for cardiovascular disease.